{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:02:39Z","timestamp":1788519759566,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12185-025-04100-2","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T12:55:54Z","timestamp":1762692954000},"page":"385-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Senpuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Oshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"5","key":"4100_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"5","key":"4100_CR2","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/curroncol30050334","volume":"30","author":"BE Monteith","year":"2023","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023;30(5):4382\u2013401. https:\/\/doi.org\/10.3390\/curroncol30050334.","journal-title":"Curr Oncol"},{"issue":"9","key":"4100_CR3","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103(9):e412\u20135. https:\/\/doi.org\/10.3324\/haematol.2017.183475.","journal-title":"Haematologica"},{"issue":"9","key":"4100_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5(9):e349. https:\/\/doi.org\/10.1038\/bcj.2015.79.","journal-title":"Blood Cancer J"},{"issue":"15","key":"4100_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","journal-title":"J Clin Oncol"},{"issue":"26","key":"4100_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"29","key":"4100_CR7","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318. https:\/\/doi.org\/10.1200\/JCO.21.02614.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4100_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/1097-0142(19870901)60:5<1060::aid-cncr2820600522>3.0.co;2-3","volume":"60","author":"A Carter","year":"1987","unstructured":"Carter A, Hocherman I, Linn S, Cohen Y, Tatarsky I. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer. 1987;60(5):1060\u20135. https:\/\/doi.org\/10.1002\/1097-0142(19870901)60:5%3c1060::aid-cncr2820600522%3e3.0.co;2-3.","journal-title":"Cancer"},{"issue":"3","key":"4100_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000204735","volume":"87","author":"H Murakami","year":"1992","unstructured":"Murakami H, Nemoto K, Sawamura M, Tamura J, Matsushima T, Naruse T, et al. Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol. 1992;87(3):113\u20137. https:\/\/doi.org\/10.1159\/000204735.","journal-title":"Acta Haematol"},{"issue":"4","key":"4100_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0925-5710(95)00363-w","volume":"61","author":"MM Kawano","year":"1995","unstructured":"Kawano MM, Mihara K, Tsujimoto T, Huang N, Kuramoto A. A new phenotypic classification of bone marrow plasmacytosis. Int J Hematol. 1995;61(4):179\u201388. https:\/\/doi.org\/10.1016\/0925-5710(95)00363-w.","journal-title":"Int J Hematol"},{"issue":"8","key":"4100_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0803-3","volume":"33","author":"N Iriyama","year":"2016","unstructured":"Iriyama N, Miura K, Hatta Y, Uchino Y, Kurita D, Takahashi H, et al. Plasma cell maturity as a predictor of prognosis in multiple myeloma. Med Oncol. 2016;33(8):87. https:\/\/doi.org\/10.1007\/s12032-016-0803-3.","journal-title":"Med Oncol"},{"issue":"9","key":"4100_CR12","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1080\/10428194.2019.1574003","volume":"60","author":"S Oka","year":"2019","unstructured":"Oka S, Ono K, Nohgawa M. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib. Leuk Lymphoma. 2019;60(9):2152\u20137. https:\/\/doi.org\/10.1080\/10428194.2019.1574003.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4100_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1298-5","volume":"36","author":"K Kurihara","year":"2019","unstructured":"Kurihara K, Iriyama N, Miura K, Uchino Y, Takahashi H, Nakagawa M, et al. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy. Med Oncol. 2019;36(9):75. https:\/\/doi.org\/10.1007\/s12032-019-1298-5.","journal-title":"Med Oncol"},{"issue":"12","key":"4100_CR14","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4100_CR15","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3892\/ol.2017.5920","volume":"13","author":"N Iriyama","year":"2017","unstructured":"Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13(5):3803\u20138. https:\/\/doi.org\/10.3892\/ol.2017.5920.","journal-title":"Oncol Lett"},{"issue":"8","key":"4100_CR16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4100_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4100_CR18","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907\u201316. https:\/\/doi.org\/10.1182\/blood-2005-08-3531.","journal-title":"Blood"},{"key":"4100_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-065x.2003.00040.x","volume":"194","author":"KI Lin","year":"2003","unstructured":"Lin KI, Tunyaplin C, Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev. 2003;194:19\u201328. https:\/\/doi.org\/10.1034\/j.1600-065x.2003.00040.x.","journal-title":"Immunol Rev"},{"issue":"4","key":"4100_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ni907","volume":"4","author":"NN Iwakoshi","year":"2003","unstructured":"Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4(4):321\u20139. https:\/\/doi.org\/10.1038\/ni907.","journal-title":"Nat Immunol"},{"issue":"2","key":"4100_CR21","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3324\/haematol.2013.090142","volume":"99","author":"M Gambella","year":"2014","unstructured":"Gambella M, Rocci A, Passera R, Gay F, Omed\u00e8 P, Crippa C, et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 2014;99(2):e14\u20136. https:\/\/doi.org\/10.3324\/haematol.2013.090142.","journal-title":"Haematologica"},{"issue":"11","key":"4100_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-020-01423-4","volume":"37","author":"M Okura","year":"2020","unstructured":"Okura M, Ida N, Yamauchi T. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Med Oncol. 2020;37(11):103. https:\/\/doi.org\/10.1007\/s12032-020-01423-4.","journal-title":"Med Oncol"},{"issue":"6","key":"4100_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.96.016","volume":"96","author":"T Ito","year":"2020","unstructured":"Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(6):189\u2013203. https:\/\/doi.org\/10.2183\/pjab.96.016.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"3","key":"4100_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030963","volume":"15","author":"P Kulig","year":"2023","unstructured":"Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machali\u0144ski B. Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives. Cancers (Basel). 2023;15(3):963. https:\/\/doi.org\/10.3390\/cancers15030963.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4100_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1532\/IJH97.05112","volume":"83","author":"K Otsuyama","year":"2006","unstructured":"Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83(1):39\u201343. https:\/\/doi.org\/10.1532\/IJH97.05112.","journal-title":"Int J Hematol"},{"key":"4100_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168. https:\/\/doi.org\/10.1016\/j.blre.2024.101168.","journal-title":"Blood Rev"},{"issue":"6","key":"4100_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3892\/ol.2024.14391","volume":"27","author":"N Liu","year":"2024","unstructured":"Liu N, Xie Z, Li H, Wang L. The numerous facets of 1q21+ in multiple myeloma: pathogenesis, clinicopathological features, prognosis and clinical progress (Review). Oncol Lett. 2024;27(6):258. https:\/\/doi.org\/10.3892\/ol.2024.14391.","journal-title":"Oncol Lett"},{"issue":"17","key":"4100_CR28","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2400712.","journal-title":"N Engl J Med"},{"issue":"4","key":"4100_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04100-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:10:47Z","timestamp":1772889047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04100-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04100-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Noriyoshi Iriyama received honoraria and speaker fees from Novartis Pharma, Pfizer, Ono Pharmaceutical, Otsuka Pharmaceutical, AbbVie GK, Nippon Shinyaku, Chugai Pharmaceutical, Janssen Pharmaceutical, Meiji Seika Pharma, and Asahi Kasei Pharma. Hitomi Nakayama received honoraria from Sanofi and Janssen Pharmaceutical. Masaru Nakagawa received honoraria from Chugai Pharmaceutical, Janssen Pharmaceutical, Sanofi, Novartis Pharma, Ono Pharmaceutical, AbbVie GK, Takeda Pharmaceutical, Asahi Kasei Pharma, AstraZeneca K.K, and Daiichi Sankyo Company. Atsushi Takahata received honoraria from Janssen Pharmaceutical, Bristol Myers Squibb, and Sanofi. Eriko Sato received honoraria from Janssen Pharmaceutical, Pfizer, Ono Pharmaceutical, and Sanofi. Kohtaro Toyama received honoraria from Novartis Pharma, AbbVie GK, Chugai Pharmaceutical, Sanofi, Ohara Pharmaceutical, and AstraZeneca K.K. Toshiaki Hayashi received honoraria from Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, and Ono Pharmaceutical. Yuki Osada received honoraria from Janssen Pharmaceutical. Junichi Watanabe received honoraria from Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, Pfizer, Fujimoto Pharmaceutical, Ono Pharmaceutical, and Takeda Pharmaceutical. Yasunobu Sekiguchi received honoraria from Chugai Pharmaceutical and AbbVie GK. Gaku Oshikawa received honoraria from Janssen Pharmaceutical KK, Bristol Myers Squibb, Takeda Pharmaceutical, Pfizer, Ono Pharmaceutical, Chugai Pharmaceutical, Sanofi, and Towa Pharmaceutical. Michihide Tokuhira received honoraria from Janssen Pharmaceutical, Bristol Myers Squibb, and Sanofi. Ken Suzuki received honoraria from Bristol Myers Squibb, Novartis Pharma, Takeda Pharmaceutical, and Ono Pharmaceutical. Takashi Kumagai received honoraria from Janssen Pharmaceutical KK, Bristol Myers Squibb, Novartis Pharma, Takeda Pharmaceutical, Pfizer, and Ono Pharmaceutical, and honoraria and research funds from Chugai Pharmaceutical. Katsuhiro Miura received honoraria and speaker fees from Chugai Pharmaceutical, Janssen Pharmaceutical, Nippon Shinyaku, AstraZeneca, AbbVie GK, Daiichi Sankyo, Kyowa Kirin, Novartis Pharma, Takeda Pharmaceuticals, Ono Pharmaceutical, and Bristol Myers Squibb. Takehiko Mori received honoraria from Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, Pfizer, Fujimoto Pharmaceutical, Ono Pharmaceutical, and Takeda Pharmaceutical. The remaining authors declare no conflicts of interest regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}